<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3869">
  <stage>Registered</stage>
  <submitdate>20/02/2013</submitdate>
  <approvaldate>20/02/2013</approvaldate>
  <nctid>NCT01797419</nctid>
  <trial_identification>
    <studytitle>Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)</studytitle>
    <scientifictitle>A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Ranging Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5806 in Subjects &lt; 24 Months of Age Hospitalized for Respiratory Syncytial Virus (RSV) Related Respiratory Infection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GS-US-218-0104</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Respiratory Syncytial Virus Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GS-5806
Treatment: drugs - Placebo

Experimental: GS-5806 - Single dose, oral liquid, .5 mL/kg

Placebo Comparator: Placebo - Single dose, oral liquid, .5 mL/kg


Treatment: drugs: GS-5806
Single dose, oral liquid, .5 mL/kg

Treatment: drugs: Placebo
Single dose, oral liquid, .5 mL/kg

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability - Safety and tolerability will be assessed by evaluating AE's, laboratory abnormalities and vital sign measurements.</outcome>
      <timepoint>10 days from subject randomization to study drug</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics effects of GS-5806 - Evaluation of GS-5806 on viral load related and symptom related endpoints.</outcome>
      <timepoint>10 days from subject randomization to study drug</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  &lt;24 months of age

          -  Diagnosis of Respiratory Syncytial Virus (RSV) within 48 hours of screening</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>24</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Chronic or congenital heart disease

          -  Required ventilation or admission to any pediatric Intensive Care Unit

          -  Inadequate organ function</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/05/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>0</actualsamplesize>
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2013</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Geelong Hospital - Geelong</hospital>
    <hospital>Monash Medical Center - Clayton</hospital>
    <hospital>Queensland Children's Medical Research Unit - Herston</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Women's and Children's Hospital Adelaide - North Adelaide</hospital>
    <hospital>Royal Children's Hospital - Parkville</hospital>
    <hospital>Sydney Children's Hospital - Randwick</hospital>
    <hospital>Princess Margaret Hospital for Children - Subiaco</hospital>
    <hospital>Westmead Children's Hospital - Westmead</hospital>
    <postcode>3220 - Geelong</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Herston</postcode>
    <postcode> - Hobart</postcode>
    <postcode> - North Adelaide</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - Randwick</postcode>
    <postcode> - Subiaco</postcode>
    <postcode> - Westmead</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of
      GS-5806 in hospitalized infants with RSV.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01797419</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Sly, MD</name>
      <address>Queensland Children's Medical Research Unit, Herston, AUS</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>